BioSpace News Archive

Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will present posters at four upcoming U.S. and international medical conferences in September.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the opening of nine additional sites for recruitment into its pivotal NAV3-33 Phase 3 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA).

On August 31, 2022, Venus Medtech Inc., a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its interim results for the six months ended June 30, 2022.

Aston Sci. Inc., a clinical stage biopharmaceutical company specializing in clinical development of therapeutic cancer vaccines, announced that it obtained IND approval from the U.S. Food and Drug Administration (FDA) for Phase 2 clinical trial of its main product, AST-301 (HER2-ICD vaccine).

iCare Health Solutions, a VSP Vision™ company, announced Stephen Kendig as its new Chief Operating Officer.

4DMedical, the leading developer of functional imaging software for respiratory illness, announced successful completion of a study by Vanderbilt University Medical Center of post-deployment veterans referred by the Nashville VA.

Fuzionaire, Inc. today announced a collaborative research agreement with McGill University that will leverage the company’s proprietary alkali metal catalyst platform in creating novel heterocyclic, biologically active, silicon-containing scaffolds and new silicon-based drug candidates.

Cue Health (“Cue”) (Nasdaq: HLTH) today announced that it has made a de novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue® Flu Molecular Test for at-home and point-of-care (POC) use.

Vida Health, a leader in virtual cardiometabolic healthcare, is hiring a team of endocrinologists as it continues to expand towards higher acuity treatments.